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we	 realise	 that	 our	 waning	 arsenal	 may	 not	 hold	 for	 much	 longer	 against	 the	
resurgence	of	illnesses	previously	consigned	to	history.	Bacteria	have	succeeded	in	
evolving	strains	 resistant	 to	almost	every	drug	 that	we	have	 thrown	at	 them,	and	
therein	lies	the	challenge	ahead.	Scientists	across	many	fields	must	work	together	in	
order	to	stay	one	step	ahead	of	the	constantly	evolving	bacteria.	We	must	develop	








of	 these	molecules.	 Because	 this	 templated	 combination	 blocks	 the	 active	 site,	 it	
prevents	the	normal	jobs	of	enzyme	from	taking	place,	deactivating	the	enzyme.	We	
have	 chosen	 a	 selection	 of	 enzymes	 that	 are	 critical	 for	 the	 survival	 of	 various	






DCC	 experiment.	 In	 this	 thesis,	 we	 describe	 how	we	 have	 developed	 these	 DCC-
monitoring	techniques	to	allow	us	to	use	larger	numbers	of	compounds,	giving	the	
enzyme	a	greater	selection	and	increasing	the	chance	it	of	templating	a	combination	








combined	 into	 a	 single	 step.	 A	 labile	 functionality	 between	 fragments	 allows	 the	
biological	target	to	self-select	binders	from	a	dynamic	combinatorial	library	(DCL)	of	
interconverting	 building	 blocks.	 The	 scope	 of	 suitable	 reversible	 reactions	 that	
proceed	under	thermodynamic	control	in	physiological	conditions	has	been	gradually	
expanded	over	the	last	decades,	however	DCC	has	thus	far	failed	to	gain	traction	as	
a	 technique	 appropriate	 for	 drug	 discovery	 in	 the	 pharmaceutical	 industry.	 The	
constraints	placed	on	library	size	by	validated	analytical	techniques,	and	the	effort-
intensive	 reality	 of	 this	 academically	 elegant	 concept	 have	 not	 allowed	 DCC	 to	







and	non-biological	DCC	 campaigns,	 the	method	was	developed	 to	 circumvent	 the	
undesired	 equilibrium-perturbing	 side	 effects	 arising	 from	 sample-consuming	
analytical	methods.	The	N-acylhydrazone	(NAH)	DCL	equilibrated	rapidly	at	pH	6.2	
using	 4-amino-L-phenylalanine	 (4-APA)	 as	 a	 novel,	 physiologically	 benign,	
nucleophilic	 catalyst.	 The	 DCL	was	 designed	 to	 target	b-ketoacyl-ACP	 synthase	 III	
(FabH),	an	essential	bacterial	enzyme	and	antibiotic	target.	From	the	5-membered	










prevented	 us	 from	 proceeding.	 Thus,	 we	 used	 mass	 spectrometry,	 NMR	 and	
molecular	modelling	to	show	that	HR45	acts	by	 forming	a	covalent	adduct	with	S.	
aureus	FabH.	The	5-chloro	substituent	directs	attack	from	the	nucleophilic	thiol	side	




Electrospray	 ionisation	 mass	 spectrometry	 (ESI-MS)	 is	 a	 powerful	 technique	 that	
allows	 for	 larger	DCLs	by	eliminating	 the	 size-limitations	 imposed	by	 the	need	 for	
spectral	 or	 chromatographic	 resolution	of	DCL	members.	We	developed	 a	 4-APA-
catalysed	NAH	library	targeting	the	pyridoxal	5’-phosphate	(PLP)	dependent	enzyme	





the	 DCC	 experiment	 correlated	 well	 with	 differential	 scanning	 fluorimetry	 (DSF)	
results.	Of	these	hits,	5	compounds	were	selected	for	further	study.	In	vivo	activity	
was	displayed	by	2	compounds	against	E.	coli	and	the	ESKAPE	pathogen	A.	baumannii.	













The	 field	 of	 combinatorial	 chemistry	 has	 received	 widespread	 attention	 since	 its	
advent	 in	 the	 late	 1980s1,2.	 In	 cleverly	 applying	 synthetic	 organic	 chemistry,	
combinatorial	chemistry	presents	a	rapid	and	cost-effective	route	to	large	libraries	
through	the	rational	selection	of	 irreversible	chemical	reactions	that	proceed	with	
high	yield	and	 specificity.	 The	 technique	has	been	particularly	 instrumental	 in	 the	
















error-checking	 and	 proof-reading	 functions	 carried	 out	 in	 nature	 by	 reversible	
reactions4–6.	To	further	develop	and	demonstrate	the	ingenuity	of	the	concept,	DCC	
has	since	been	successfully	applied	by	many	academic	groups	to	a	variety	of	different	
fields	 including	dynamic	polymers7,	 self-assembly	 systems8–11	and	sensor	design12.	






and	 has	 thus	 far	 failed	 to	 deliver	 any	 drug	 candidates	 to	 the	 clinic.	 A	 significant	
weakness	 of	 DCC	 lies	 in	 the	 lack	 of	 a	 robust	 and	widely	 reproducible	method	 to	



























of	 DCC,	 the	 3D	 architecture	 of	 the	 protein	 active	 site	 acts	 as	 a	 template	 on	 the	





active15,16.	 The	 largest	 obstacle	 to	 protein-templated	 DCC	 is	 the	 requirement	 to	













Firstly,	 the	 building	 blocks	 must	 be	 carefully	 selected.	 Either	 by	 building	 on	 the	




present.	 For	 these	 interactions	 to	 be	 optimised,	 geometric	 organisation	 can	 be	
achieved	by	using	a	core	scaffold.	This	may	be	a	known	substrate	of	the	target,	whose	
binding	properties	can	be	exploited	and	improved,	or	simply	a	central	organisational	
structure	with	 carefully	 determined	 vectors	 and	 topicity17.	Most	 importantly,	 the	
	
17	
building	blocks	must	 all	 be	 sufficiently	 soluble	 and	 functionalised	with	 a	 chemical	
handle	 to	 allow	 them	 to	 take	 part	 in	 the	 selected	 reversible	 reaction.	 This	
functionality	 should	 not	 interfere	with	 the	 recognition	 event,	 and	 they	 should	 be	
orthogonal	 in	 that	 there	are	no	competing	 reactions	with	other	 functionalities	on	
library	members,	or	with	residues	on	the	target.	Ideally	the	building	blocks	should	be	










the	 target,	 as	 this	 would	 prevent	 recognition	 events	 from	 taking	 place.	 In	 many	























size	 exclusion	 chromatography	 (SEC)29,	 nuclear	 magnetic	 resonance	 (NMR)	
spectroscopy30,31,	 X-ray	 crystallography32,	 fluorescence	 assay33–35,	 dynamic	
deconvolution22,36,37	and	mass	spectrometry	(MS)38–42.	While	each	technique	has	its	
benefits,	 many	 suffer	 from	 drawbacks	 that	 occur	 with	 increasing	 library	 size.	
Techniques	involving	spectral	or	chromatographic	identification	often	require	library	
members	to	be	 individually	synthesised	for	characterisation,	and	other	techniques	
are	 simply	 not	 amenable	 to	 developing	 a	 results-driven	 drug	 discovery	 platform.	
These	 cumbersome	 and	 time	 consuming	 DCL	 analysis	 methods	 detract	 from	 the	
elegance	and	efficiency	of	a	DCC	experiment,	and	may	carry	some	of	the	blame	for	





























Congreve	 et	 al.	 developed	 a	 technique	 called	 dynamic	 combinatorial	 X-ray	
crystallography	(DCX)	to	analyse	a	hydrazone	DCL	targeting	cyclin-dependent	kinase	
2	 (CDK2),	 an	 enzyme	 implicated	 in	 a	 number	 of	 cancers32.	 Their	 30-member	
hydrazone	 library	 was	 equilibrated	 over	 48	 h	 in	 the	 presence	 of	 CDK2	 crystals.	
Electron	density	maps	 confirmed	 that	 a	 single	hydrazone	A5B2	had	bound	 to	 the	
crystal,	which	was	found	to	have	an	IC50	of	30	µM.	Congreve	et	al.	recognised	that	a	
drawback	of	previously	published	DCC	experiments	was	that	amplification	could	only	
be	 detected	 by	 comparing	 identical	 libraries	 in	 the	 presence	 and	 absence	 of	 the	
	
21	
target	 protein.	 Instead	 they	 sought	 to	 use	 the	 dynamic	 nature	 of	 the	 library	 to	
discriminate	against	non-binding	species,	shrinking	the	effective	number	of	 library	
members.	This	was	the	 first	example	of	a	direct	screening	method	for	analysing	a	













of	NAH	exchange	are	extremely	 slow	at	physiological	 pH	and	 require	 a	pH	<	4	 to	
equilibrate	 on	 a	 reasonable	 timescale,	 making	 the	 reaction	 unsuitable	 for	 most	
proteins36.	To	combat	this,	Bunyapaiboonsri	et	al.	assembled	a	DCL	of	66	possible	
products,	which	was	equilibrated	for	1	week	at	pH	4.	Once	the	DCL	had	equilibrated,	

































The	 next	 significant	 evolution	 in	NAH	 exchange	 for	DCC	 came	when	Dawson	 and	
colleagues	applied	earlier	work	by	Cordes	and	Jencks	on	the	use	of	aniline	to	catalyse	
semicarbazone	formation	(Fig.	1.6)46,47.	Dirksen	et	al.	 investigated	the	nucleophilic	
catalysis	 of	 aniline	 on	 the	 formation	 and	 hydrolysis	 of	 NAH	 peptides.	 A	 common	
problem	among	previous	NAH	examples	was	that	the	formation	of	hydrazones	was	
relatively	 rapid	 (ca.	 24	 h),	 but	 the	 hydrolysis	 reaction	 was	 slow	 (days	 to	 weeks).	
Dirksen	et	al.	showed	that	aniline	could	impart	a	70-fold	rate	enhancement	with	no	
effect	 on	 the	 rate	 constant,	 expediting	 NAH	 equilibration	 by	 allowing	 both	 the	
hydrolysis	and	formation	reactions	to	complete	within	the	space	of	hours	at	near-
physiological	 pH	 (5.7).	 They	 proposed	 that	 aniline-mediated	 transimination	












Aniline-mediated	NAH	 catalysis	was	 leveraged	 by	Greaney	 and	 Campopiano,	who	





GST	 substrate,	 chloro-2,4-dinitrobenzene	 (Fig.	 1.7).	 To	 kinetically	 freeze	 their	
equilibrated	DCL	for	HPLC	analysis,	they	increased	the	pH	to	8	with	the	addition	of	
NaOH.	 This	 effectively	 stops	NAH	exchange,	 even	 in	 the	presence	on	 aniline.	 The	
protein	was	then	removed	from	the	sample	by	ultrafiltration	and	analysed	by	HPLC.	
Elegantly,	 the	DCL	was	 separately	 templated	by	 two	different	GST	 isoforms,	 each	
resulting	in	different	amplified	species.	NAH	3g	was	amplified	in	the	presence	of	the	
helminth	worm	Schistosoma	Japonicum	isoform	(sjGST),	and	NAH	3c	was	amplified	




assay	 the	 amplified	 hits,	 so	 they	 conjugated	 aldehyde	 1	 to	 glutathione	 (GS),	
increasing	 both	 solubility	 and	 recognition	 elements	 for	 the	 enzyme.	 The	 second-
generation	GS-conjugated	library	afforded	the	same	hits,	with	IC50	values	of	22	µM	
and	57	µM	against	sjGST	and	hGST,	respectively	(see	fig.	1.7)20.	This	demonstrates	
both	 the	 sensitivity	 of	 a	DCL,	 and	 its	 use	 not	 only	 in	 identifying	 binders,	 but	 also	
mapping	active	site	interactions.	GST	has	a	highly	specific	G-site	and	non-specific	and	
notoriously	 hard	 to	 target	 H-site.	 The	 GS-conjugated	 DCL	 allowed	 Bhat	 et	 al.	 to	













a	DCL	 targeting	 the	 aspartic	 protease	endothiapepsin30.	 By	 analysing	X-ray	 crystal	
structures	 of	 the	 protein	 in	 different	 binding	 modes	 and	 co-crystallised	 with	 11	
fragments,	they	identified	moieties	capable	of	binding	in	different	conformations	of	
the	2	discreet	binding	pockets.	Using	molecular	modelling,	they	proposed	a	series	of	




membered	 libraries	 (fig.	 1.8).	 The	 5	 DCLs	were	 pre-equilibrated	 over	 24	 h	 in	 the	
absence	of	aniline	before	the	enzyme	was	added	and	each	system	was	separately	
analysed	by	1H	saturation	transfer	difference	(STD)	NMR	to	identify	binders.	Since	the	
optimum	 operating	 pH	 of	 endothiapepsin	 is	 4.6,	 it	 allowed	 Mondal	 et	 al.	 to	
equilibrate	the	library	in	the	absence	of	aniline30.	This	represents	a	rare	example	of	a	
protein	 that	 is	 amenable	 to	 catalyst-free	NAH	DCC.	 From	 the	5	 sub-libraries,	 they	
identified	8	binders	which	were	validated	as	inhibitors	by	enzymatic	assay	with	IC50s	
in	 the	 low	 micromolar	 range.	 The	 binding	 mode	 of	 two	 of	 the	 identified	 NAH	
inhibitors	was	confirmed	by	co-crystal	structures	with	the	protein.	Whereas	1H-STD	
NMR	would	not	be	appropriate	for	analysing	larger,	more	diverse	DCLs	due	to	issues	
with	 spectral	 overlap,	 cost	 and	 the	 quantity	 of	 protein	 required,	 Mondal	 et	 al.	














While	many	of	DCC	 analysis	 techniques	 of	NAH	DCLs	 have	 been	discussed	 in	 this	



























10	 HPLC	 22	 20	
Glutathione	S-
transferase	







25	 1H	STD	NMR	 12.8	 30	
Aspartic	protease	
endothiapepsin	
9	 Fluorescence	assay	 85	 33	
GABA	transporter	1	
(GAT1)	a	
36	 LC-ESI-MS/MS	 0.66	 41	
Cyclin-dependent	kinase	
2	(CDK2)	a	
30	 X-ray	crystallography	 0.03	 32	
	
Table	1.1	-	DCC	studies	searching	for	biologically	active	compounds	using	DCLs	based	





dubbed	 privileged	 structures	 owing	 to	 the	 wide	 scope	 of	 activity	 that	 NAH	 lead	
compounds	 have	 shown48.	 There	 are	 literature	 examples	 of	 NAHs	 with	
anticonvulsant,	 antidepressant,	 analgesic,	 antimalarial,	 antimicrobial,	
antimycobacterial,	antitumoural	and	antiviral	activities49.	Recently,	NAHs	have	been	













Since	 the	 advent	 of	 fragment-based	 drug	 discovery	 (FBDD)	 30	 years	 ago,	 several	
industrial	and	academic	groups	have	adopted	the	approach	and	it	has	resulted	in	over	
30	 candidates	 reaching	 the	 clinic,	 with	 Vemurafenib	 (Plexxikon)	 and	 Venetoclax	
(AbbVie,	 Genentech)	 winning	 FDA	 approval52.	 The	 idea	 of	 dynamic	 combinatorial	
chemistry	(DCC)	in	the	context	of	drug	discovery	was	born	at	approximately	the	same	
time,	 and	 the	 two	 have	 evolved	 alongside	 one	 another.	 The	 striking	 difference	
























Carcelli et al., 
Influenza virus PA nuclease inhbitor
Rodrigues et al. 
























of	 a	 target	 protein,	 and	 the	 distribution	 of	 ligands	 in	 each	 is	 compared54.	 The	
complexity	 of	 a	 DCC	 experiment	 increases	 with	 library	 size,	 owing	 to	
chromatographic	or	 spectral	overlap	 in	 common	deconvolution	 techniques	 (HPLC,	
NMR)54.	 Additionally,	 the	 requirement	 to	 synthesise	 each	 possible	 library	






existing	DCL	analysis	and	devise	new	methods	 to	address	existing	 issues,	with	 the	
hope	 of	 taking	 DCC	 a	 step	 further	 towards	 acceptance	 as	 a	 results-driven	 drug	















workers	 in	 a	 small	 screen	 of	 dyes	 for	 antibacterial	 activity56.	 In	 the	 early	 1940s,	
Selman	 Waksman	 developed	 the	 first	 platform	 to	 screen	 soil	 bacteria	 for	






attempted	synthesis	of	 the	antimalarial	drug	chloroquine58.	By	the	 late	1960s,	 the	
discovery	 output	 from	 the	 Waksman	 platform	 had	 dried	 up.	 In	 response,	 the	
community	 began	 filling	 the	 pipeline	 with	 synthetic	 analogues	 of	 previously	
discovered	natural	products.	This	was	to	spell	the	end	of	the	golden	era	of	antibiotic	






rapid	 advances	 in	 synthetic	medicinal	 chemistry.	However,	 despite	 initial	 promise	
and	huge	investment,	the	small-molecule	approach	in	the	search	for	antibiotics	has	
proved	 astoundingly	 barren.	 High-throughput	 screening	 (HTS)	 failed	 to	 produce	 a	
single	 compound	with	 a	 reasonable	 spectrum	of	 in	 vivo	 activity	 until	 1997,	when	
bedaquiline	was	discovered	to	have	specific	antibacterial	activity	in	a	HTS	campaign	
against	 mycobacteria59.	 Many	 lead	 compounds	 with	 in	 vitro	 activity	 have	 been	
generated	against	both	Gram-positive	and	Gram-negative	bacterial	targets,	however	
none	of	these	have	been	translated	into	clinically	useful	molecules.	This	failure	has	
been	 attributed	 to	 the	 fact	 that	 bacterial	 cells	 do	 not	 conform	 to	 the	 rules	 that	










protected,	 with	 an	 outer	 membrane	 that	 prevents	 the	 passage	 of	 amphipathic	
molecules	(a	feature	of	most	small-molecule	drugs	to	increase	their	bio-availability).	
Bacteria	have	also	evolved	multidrug-resistant	 (MDR)	efflux	pumps	 that	 remove	a	
wide	variety	of	structurally	unrelated	compounds	from	the	cell,	with	high	specificity	
for	 hydrophobic	 cations61.	 Finally,	 to	 complete	 the	 defence	 system	 the	 inner	
membrane	 poses	 a	 barrier	 to	 hydrophilic	 compounds.	 Almost	 all	 established	






currently	 only	 infect	 a	 small	 minority	 of	 patients.	 Ethical	 concerns	 also	 prevent	












































poor	 return	on	 investment	 in	antibiotic	 research;	a	 therapy	course	 is	 typically	1-2	
weeks	long,	and	owing	to	the	inevitable	problem	of	antibiotic	resistance	the	drug	will	
have	 a	 finite	 useful	 lifetime.	 The	 global	 community	 is	 beginning	 to	 respond	with	
initiatives	such	as	the	approval	of	the	GAIN	(Generate	Antibiotic	Incentives	Now)	Act	
in	the	US	in	2012,	and	the	WHO	Global	Action	Plan	on	Antimicrobial	Resistance,	which	















(XDR)	 species.	 These	 include	both	Gram-positive	 and	Gram-negative	bacteria	 that	
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commonly	 cause	 nosocomial	 or	 community	 infections.	 These	 have	 been	 dubbed	
ESKAPE	 pathogens	 (Enterococus	 faecium,	 Staphylococcus	 aureus,	 Klebsiella	
pneumoniae,	Acinetobacter	baumannii,	Pseudomonas	aeruginosa,	and	Enterobacter	







of	 antibiotics.	 By	 destruction,	 modification,	 efflux	 or	 subverting	 specific	 cellular	




a	 relapse	 of	 infection	 and	 accelerates	 the	 development	 of	 antibiotic-resistant	
mutants56.	We	are	faced,	therefore,	with	an	urgent	need	to	develop	not	only	new	




















experiments	 are	 developed,	will	 DCC	 become	 a	 genuine	 alternative	 to	 traditional	
drug	discovery	platforms.	In	this	chapter,	we	discuss	the	construction	of	a	dynamic	
combinatorial	library	(DCL)	targeting	b-ketoacyl-ACP	synthase	III	(FabH),	an	essential	
bacterial	 enzyme	 involved	 in	 fatty	 acid	 biosynthesis.	 The	 DCL	 was	 developed	
specifically	to	contain	fluorine-labelled	products.	This	allowed	the	DCC	reaction	to	be	
monitored	 non-invasively	 by	 19F	 NMR	without	 the	 need	 for	 destructive	 analytical	
methods,	which	we	believe	perturb	the	finely	balanced	equilibrium	attained	during	a	
DCC	experiment.	From	the	5-membered	DCL,	a	single	combination	was	identified	as	






derived	 from	 short-chain	 acyl-CoAs.	Higher	 eukaryotes	 possess	 a	 single	 gene	 that	
encodes	a	large	protein	termed	fatty	acid	synthase	I	(FAS	I),	which	contains	all	of	the	
functionalities	required	to	produce	a	fatty	acid67.	In	bacteria,	FAS	is	carried	out	in	an	
analogous	 process	 by	 fatty	 acid	 synthase	 II	 (FAS	 II),	 a	 dissociated	 system	 where	
individual	proteins,	each	responsible	for	a	single	step	in	the	pathway,	are	coded	for	
by	separate	genes.	Whilst	there	is	homologous	architecture	between	functionalities	
in	 FAS	 I	 and	 FAS	 II,	 there	 are	 also	 significant	 differences	 that	 make	 the	 systems	
distinct.	FAS	II	is	not	only	responsible	for	producing	long-chain	fatty	acids,	as	when	
the	growing	 fatty	acid	 chain	 is	 carried	between	FAS	 II	proteins	by	 the	acyl	 carrier	
protein	 (ACP),	 the	 intermediates	 may	 be	 diverted	 into	 other	 biosynthetic	
pathways67,68.	 These	 attributes	 make	 the	 essential	 bacterial	 process	 of	 FAS	 II	 an	
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attractive	 target	 for	 the	development	of	new	antimicrobials69.	 FAS	 II	 in	E.	 coli	has	
been	 regarded	 as	 a	 model	 system,	 and	 although	 the	 biosynthetic	 pathway	 is	
























first	 undergoes	 transacylation	 and	 is	 sequestered	 on	 the	 active	 site	 cysteine-112	
residue	with	the	release	of	CoA.	Malonyl-ACP	is	then	decarboxylated	and	stabilised	













malonyl-ACP	 to	 produce	 the	 C4	 β-ketoacyl-ACP,	 FabH	 plays	 an	 important	 role	 in	
mediating	 the	 fatty	 acid	 composition	 of	 the	 organism.	 Although	 the	 active	 site	
residues	and	peptide	sequence	remain	highly	conserved	across	both	Gram-positive	
and	Gram-negative	bacteria77,	small	structural	differences	in	the	acyl-binding	pocket	






















structures	 of	 FabH	 with	 acetyl-CoA	 show	 the	 substrate	 binding	 in	 a	 ‘fish-hook’	










Figure	2.3	 -	 Schematic	 representation	of	 the	 catalytic	mechanism	of	 the	 two-step	
condensation	performed	by	FabH.	1	-	Acetyl-CoA	is	sequestered	in	the	active	site	and	
attacked	by	nucleophilic	C112.	2	-	The	tetrahedral	intermediate	is	stabilised	by	C112.	





At	 the	 base	 of	 the	 CoA	 binding	 channel	 sits	 the	 catalytic	 triad	 of	 Cys-His-Asn.	
Substitution	studies	have	shown	that	each	residue	is	fundamental	for	turnover	and	
each	 has	 its	 own	 role	 in	 the	 two-step	 catalytic	 process.	 The	 C112	 residue	 is	
responsible	for	sequestering	acetyl-CoA	by	transacylation.	The	nucleophilicity	of	the	









ACP	 or	 subsequent	 condensation	 with	 the	 C112-sequestered	 acetyl	 group75.	 The	
orientations	of	H244	and	N274	are	fixed	by	a	network	of	hydrogen	bonds,	resulting	
in	 the	 proton	 donating	 moieties	 of	 both	 residues	 pointing	 in	 the	 same	 direction	
forming	 an	 oxyanion	 hole	 that	 stabilises	 the	 developing	 negative	 charge	 on	 the	






can	 be	 selectively	 targeted	with	minimal	 effect	 in	 humans85,86,87.	 There	 are	many	





the	 strategy	 of	 targeting	 FAS	 II	 in	 Gram-positive	 bacteria	 for	 antimicrobial	
therapeutics	 was	 questioned	 after	 findings	 that	 FAS	 II	 was	 not	 essential	 in	 S.	
agalactiae	when	the	bacteria	were	supplied	with	exogenous	fatty	acids,	as	would	be	
the	case	in	a	mammalian	host89,90.	Whether	this	conclusion	can	be	extended	to	all	











inhibit	 FabH,	 although	most	with	 poor	 efficacy.	 Thiolactomycin	 (TLM)	 is	 a	 natural	
product	that	mimics	malonyl-ACP	binding	in	the	condensing	enzymes	of	FAS	II.	TLM	
has	been	shown	to	be	specific	 for	FAS	 II	and	shows	highest	efficacy	against	FabB,	








led	 to	 a	number	of	 thiolactomycin	 analogues	 that	 show	 improved	activity	 against	
FabH93.		
	
Platensimycin	 is	 a	 potent	 natural	 product	 inhibitor	 of	 FabF	 isolated	 from	
Streptomyces	platensis	with	an	IC50	of	48	nM	against	S.	aureus	and	160	nM	against	E.	
coli	 FabF,	 however	 very	 low	 activity	 towards	 FabH.	 Structural	 data	 detailing	 the	































































(fig.	 2.7)77.	 These	were	 composed	 of	 two	 substituted	 aromatic	 rings	 joined	 by	 an	
aliphatic	linker,	Schiff	base	or	hydrazone	moiety94–100.	A	combination	of	in	vitro	and	
whole-cell	assays	showed	promising	inhibition	data,	suggesting	that	this	class	of	small	















with	 approximately	 25%	 of	 all	 marketed	 drugs	 containing	 at	 least	 one	 fluorine	
atom101.	 The	 inclusion	 of	 fluorine	 can	 help	 medicinal	 chemists	 to	 modulate	 the	


















A - IC50 = 2.5 µM
B - IC50 = 2.6 µM C - IC50 = 2.7 µM
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library	 screening	 and	 performing	 biochemical-	 and	 binding	 assays101.	 19F	 NMR	




the	 19F	 spectrum	 and	 avoid	 the	 use	 of	 expensive	 deuterated	 reagents	 while	 not	












































Figure	 2.9	 -	 Illustration	 of	 a	 19F	 NMR	 screening	 experiment	 for	 binders.	 a)	 Two	
fluorinated	 molecules	 to	 be	 screened	 against	 a	 protein	 target	 (A	 and	 B),	 and	 a	
fluorinated	 internal	 reference	 (C)	 that	 is	 known	 not	 to	 bind.	 b)	 The	 fluorinated	
internal	reference	molecule	(C)	does	not	bind	to	the	protein	and	the	breadth	of	the	
signal	remains	unchanged.	Due	to	a	combination	of	the	chemical	shift	anisotropy	and	
exchange	between	unbound	states,	 the	signal	 for	a	binding	molecule	 (A)	 is	broad,	
while	the	signal	width	for	a	non-binding	molecule	(B)	remains	unchanged.	
	








Once	binders	have	been	 identified	from	an	 initial	screen	of	 fluorinated	fragments,	
non-fluorinated	 fragments	 may	 be	 screened	 in	 competition	 assays	 against	 an	












though	 intelligent	 library	 design	 aided	 by	 increasingly	 accurate	 chemical	 shift	
prediction	 software.	More	 complex	NMR	 experiments	 have	 been	 used	 to	 resolve	
complex	 libraries	 containing	 members	 with	 overlapping	 signals,	 both	 by	 2D	






templated	DCC,	we	 sought	 to	demonstrate	 the	power	of	 the	 19F	NMR	analysis	by	
constructing	 a	 19F-labelled	 DCL	 against	 the	 antibiotic	 target	 protein	 FabH.	 We	
proposed	that	this	would	allow	us	to	monitor	the	DCL	equilibration	process	in	pseudo	











the	 construct	 by	 PCR	 and	 cloned	 into	 the	 linearised	 pGEM-T	 Easy	 vector	 with	 3’	
terminal	thymidine	(T)	overhangs.	The	pGEM	vector	allows	blue/white	screening	of	








E.	 coli	 cells,	 which	 were	 grown	 in	 LB	 under	 conditions	 that	 had	 previously	 been	











































As	 discussed	 in	 Chapter	 1,	 the	 use	 of	 aniline	 as	 a	 nucleophilic	 catalyst	 for	 N-



































































































including	 high	 water	 solubility,	 increased	 biocompatibility	 and	 lower	 safety	
requirements.	Whereas	aniline	is	a	known	toxin,	carcinogen,	mutagen	and	corrosive	
compound	 with	 harmful	 environmental	 effects,	 4-APA	 is	 only	 reported	 to	 cause	
irritation.	We	characterised	4-APA	catalysis	of	NAH	formation	by	conducting	a	simple	
reaction	between	2-fluoro-5-formylbenzoic	acid	A	and	vanillic	acid	hydrazide	5	in	the	

























10	mM	4-APA	 accelerated	 the	 forward	 reaction	 on	 a	 satisfactory	 timescale,	 both	




In	 a	 DCC	 experiment,	 it	 is	 essential	 that	 the	 reverse	 reaction	 is	 on	 a	 comparable	





reaction,	 the	 library	 was	 composed	 of	 the	 same	 fundamental	 building	 blocks,	


































both	 small	 differences	 in	 reactivity	 and	 misrepresentation	 due	 to	 unequal	
absorbance	 at	 254	 nm.	 With	 10	 mM	 4-APA	 the	 forward	 reaction	 had	 reached	
equilibrium	in	the	time	that	it	took	to	inject	the	sample	onto	the	HPLC	column,	and	




they	 had	 reached	 equilibrium,	 there	 was	 continual	 fluctuation	 in	 the	 10	 mM	
experiments.		
	
As	 already	 discussed,	 one	 caveat	 of	 a	 DCC	 experiment	 is	 that	 the	 rate	 of	 re-
equilibration	should	not	be	faster	than	the	on/off	rate	of	the	ligand	binding	to	the	








The	 structures	 of	 both	 platencin	 and	 the	 FabH	 inhibitors	 proposed	 by	 Nie	 et	 al.	
suggest	that	a	carboxylic	acid	group	proximal	to	the	base	of	the	binding	pocket	forms	
essential	 H-bonds	 with	 active-site	 residues84.	 Wang	 et	 al.	 conducted	 preliminary	
structure-activity	 relationship	 studies	 on	 their	 initial	 vanillic	 acylhydrazone	 hits,	
showing	 that	 hydroxyl	 groups	 on	 the	 aldehyde-derived	 ring	 were	 improved	 the	
potency	 of	 the	 hits94.	 In	 addition	 to	 in	 vitro	 enzymatic	 assays,	 their	 compounds	
underwent	cell-based	assays	that	showed	that	their	title	compound	E9	had	greater	
antimicrobial	 activity	 than	 kanamycin	 in	 both	 Gram-positive	 and	 Gram-negative	




















aromatic	 rings	 connected	 by	 an	 N-acylhydrazone	 linker.	 We	 began	 with	 the	










five-membered	 library	 1-5	 in	 combination	 with	 fluorinated	 aldehyde	 A.	 This	
requirement	 to	 manually	 determine	 chemical	 shifts	 is	 a	 drawback	 to	 all	 NMR	
screening	 campaigns,	 however	 this	 may	 soon	 be	 superfluous	 with	 the	 increasing	
sophistication	of	chemical	shift	prediction	software.	Interestingly,	the	sensitivity	of	








































































The	 relaxation	 rate	of	 a	nucleus	differs	between	molecules,	 and	 this	 can	 result	 in	
changes	to	the	 intensity	of	the	19F	signal.	 It	was	therefore	 important	to	conduct	a	
series	of	experiments	with	increasing	lengths	of	relaxation	time	in	the	pulse	sequence	
to	determine	if	there	was	any	observable	difference	in	the	19F	signals	between	library	
members.	 Experiments	 were	 conducted	 with	 a	 pre-equilibrated	 3-member	 DCL	
assembled	 from	 hydrazides	 3,	 4	 and	 5	 with	 aldehyde	 A	 using	 512	 scans	 with	
relaxation	times	of	1,	2,	3	or	4	seconds.	The	ratio	of	signal	integrals	was	compared	
between	different	experiments	but	it	was	apparent	that	the	relaxation	time	had	no	
effect	 on	 the	 outcome.	 This	 is	 perhaps	 not	 surprising	 as	 the	 immediate	 chemical	
environment	 surrounding	 the	 19F	 nucleus	 was	 identical	 in	 each	 compound.	 This	






































Fig.	 2.23a	 shows	 the	 19F	 spectrum	 of	 the	 control	 DCL	 in	 the	 absence	 of	 protein	
template,	8	hours	after	mixing.	It	is	interesting	to	note	that	not	all	products	are	of	





protein	 results	 in	 line	 broadening	 for	 two	 distinct	 reasons.	 Firstly,	 the	 exchange	
between	bound	and	unbound	states	of	the	fluorinated	ligand	will	cause	the	observed	
unbound	signal	to	broaden	and	begin	to	shift	either	upfield	or	downfield,	depending	











in	 appearance,	 despite	 a	 slight	 loss	 in	 integral	 relative	 to	 the	 5-FU	 control.	 The	
remaining	signals	report	the	occurrence	of	a	binding	event.	Most	significantly	the	19F	
signal	corresponding	to	A4	has	downfield	shifted	from	-111.08	ppm	to	-111.05	ppm	
with	 an	 integral	 decrease	of	 42%.	Both	 factors	 indicate	 that	 the	 ligand	 is	 present	
largely	in	its	bound	state	resonance,	however	this	corresponding	bound	state	signal	
was	 not	 detected.	 This	may	 be	 as	 it	was	 too	 broad	 to	 be	 distinguished	 from	 the	
baseline.	 Subsequent	 2-dimensional	 19F	 homonuclear	 correlation	 (COSY)	 NMR	
experiments	 also	 failed	 to	 identify	 the	bound	 state	 resonance.	 Broadening	 is	 also	










was	 used	 to	 characterise	 the	 inhibitory	 activity	 of	 compounds	A1-5.	 The	 coupled	
assay	 utilises	 the	 free	 thiol	 produced	 when	 malonyl-ACP	 and	 acetyl-CoA	 are	
condensed	 by	 FabH.	 The	 evolved	 free	 CoA-SH	 displaces	 the	 disulfide	 of	 Ellman’s	













the	data	corroborates	our	 interpretation	of	 the	 19F	DCL	experiment,	with	NAH	A4	
showing	the	highest	inhibitory	activity,	followed	by	NAH	A3	and	NAH	A5.	Despite	this	
agreement,	the	inhibitory	activity	of	these	compounds	is	very	weak,	with	the	assay	










































For	 example,	 the	 inability	 to	 account	 for	 the	 entire	 population	 of	 19F-containing	
molecules	due	to	bound-unbound	state	coalescence	represents	both	a	downfall	and	
an	opportunity	to	develop	the	technique	for	quantitative	DCL	analysis.	The	problem	
arises	 because	 by	 modern	 analytical	 chemistry	 standards,	 NMR	 is	 incredibly	
insensitive.	It	 is	entirely	plausible	that	by	a	combination	of	improved	methodology	
and	variable	 temperature	 (VT)	experiments,	 it	may	be	soon	possible	 to	 locate	 the	
bound	state	signals	for	ligands	at	DCL	concentrations.	This	will	be	essential,	not	only	
for	comparing	the	ratio	of	bound-to-unbound,	but	also	to	qualify	19F	NMR	as	a	true	



















deconvoluted	 by	 destructive	 techniques	 such	 as	 HPLC	 and	 LC-MS.	 The	 19F	 NMR	
analysis	of	our	semi-rationally	constructed	DCL	identified	a	binding	hierarchy	among	
the	 5	 products,	 which	 we	 corroborated	 by	 in	 vitro	 enzymatic	 assay.	 To	 our	
















































































overnight	 at	 37	 °C.	White	 colonies	were	 selected	over	 black	 colonies,	 picked	 into	



























































media	 (100	μL)	was	added	and	 the	mixture	was	agitated	at	37	 °C	 for	1	hour.	The	
mixture	was	spread	on	LB	agar	(30	μg/mL	kanamycin)	and	incubated	overnight	at	37	



















LB	 agar	 (30	 μg/mL	 kanamycin)	 and	 incubated	 overnight	 at	 37	 °C.	 A	 single	
transformant	was	used	to	inoculate	two	seed	cultures	of	sterile	LB	broth	(2	x	250	mL,	






N-Terminal	 histidine-tagged	 ecFabH	 was	 purified	 at	 4	 °C	 by	 Ni-affinity	
chromatography	 followed	 by	 size	 exclusion	 chromatography.	 The	 BL21	 (DE3)	 cell	
pellet	expressing	ecFabH	was	resuspended	in	lysis	buffer	(30	mL,	20	mM	Tris-HCl	pH	







































































A	 three-member	 library	 was	 assembled	 from	 NAHs	 3,	 4	 and	 5	 (200	 μM	 each)	 in	
sodium	phosphate	buffer	(50	mM,	D2O,	pH	6.2),	5-fluorouracil	(internal	standard,	200	
μM)	and	a	total	of	10%	DMSO.	A	series	of	19F	NMR	experiments	were	conducted	with	









buffer	 (1	mL,	1	M,	pH	8.0)	 and	ddH2O	 (8	mL).	 The	assay	was	 run	 in	96-well	plate	











































NMR	 (126	MHz,	 DMSO)	 δ	 165.6,	 165.1,	 152.9,	 149.1,	 146.9,	 136.0,	 133.7,	 131.2,	
130.8,	129.6,	124.1,	120.5,	118.4,	118.4,	118.2,	31.2;	19F	NMR	(470	MHz,	DMSO)	δ	-












































































128.0,	 125.8,	 120.4,	 118.1,	 35.2,	 31.4,	 31.2,	 21.5;	 19F	NMR	 (470	MHz,	 DMSO)	 δ	 -






































































147.8,	 133.4,	 133.3,	 131.6,	 130.5,	 124.5,	 121.9,	 120.4,	 120.3,	 118.3,	 118.1,	 115.5,	



















































resistance.	 Fundamental	 to	 the	 success	 of	 developing	 potent	 lead	 molecules	 is	
understanding	 the	 inhibition	 mechanisms	 of	 active	 compounds,	 such	 that	 their	
potential	may	 be	 exploited	 in	 a	 rational	manner.	 In	 this	 chapter,	 we	 describe	 an	















Drugs	 that	 form	 covalent	 bonds	 with	 their	 targets	make	 up	 a	 class	 of	molecules	
known	 as	 covalent	 inhibitors.	 Covalent	 inhibitors	 are	 traditionally	 composed	 of	 a	
recognition	element	and	a	reactive,	often	electrophilic	warhead	that	forms	a	covalent	
bond	with	nucleophilic	residues	on	the	target	protein.	The	class	can	be	divided	into	
two	 subsets,	 depending	 on	 whether	 the	 covalent	 inhibition	 is	 reversible	 on	 a	
biological	timescale.	Reversible	covalent	inhibitors	typically	bind	to	their	target	and	
subsequently	dissociate	from	it	at	a	rate	faster	than	that	at	which	the	enzyme	turns	





haloketone,	 or	 most	 commonly	Michael-type	 acceptors	 based	 on	 the	 acrylamide	
moiety110.	These	 irreversible	covalent	 inhibitors	do	not	dissociate	 from	the	target.	
These	 two	 classes	 may	 be	 further	 divided,	 depending	 on	 whether	 the	 drug	 is	
administered	 in	 its	active	form,	or	the	administered	drug	 is	metabolised	 in	vivo	 to	
unveil	the	reactive	warhead.	
	
Covalent	 inhibitors	have	attracted	 some	scepticism	 from	 the	 scientific	 community	
since	 they	 elicit	 their	 efficacy	 through	 covalent	 modification,	 and	 justifiably	 the	
pharmaceutical	 industry	has	avoided	developing	covalent	 inhibitors	due	 to	 largely	
unpredictable	and	potentially	devastating	off-target	effects	and	idiosyncratic	toxicity.	







received	 approval	 from	 the	 US	 FDA,	 is	 that	 their	 precise	 mode	 of	 action	 was	
discovered	years	after	their	therapeutic	value	was	demonstrated.	For	this	reason,	the	






cyclooxygenase	 1	 and	 2	 (COX-1	 and	 COX-2)113.	 Another	 example	 is	 the	 b-lactam	
containing	 class	 of	 antibiotics,	 which	 were	 found,	 years	 after	 their	 discovery	 by	
Fleming55,	 to	 acetylate	 bacterial	 D-ala-D-ala-transpeptidase	 (also	 known	 as	 the	
	
77	









of	 covalent	 inhibitors	 gaining	 ground	 in	 drug	 discovery,	with	 a	 new	 class	 of	 drug	
known	as	targeted	covalent	inhibitors	(TCIs)110.	The	idea	behind	TCIs	is	to	develop	a	
highly	 selective	 molecule	 that	 can	 bind	 to	 a	 target	 and	 place	 a	 weakly	 reactive	









































1,2-Dithiole-3-ones	 are	 a	 synthetic	 class	 of	 compounds	 centred	 around	 a	 5-
membered	asymmetric	ring	containing	a	disulfide	adjacent	to	a	carbonyl.	Analogous	








Anethole	 dithiolethione	 (ADT)	 has	 been	 used	 for	 decades	 as	 a	 choleretic	 and	 a	
sialogogue,	and	is	marketed	in	France	as	Sulfarlem	for	the	treatment	of	dyspepsia116.	























Figure	3.3	 -	 The	 structures	of	ADT	and	Oltipraz,	 examples	of	 1,2-dithiole-3-thione	
drugs.	
	
Oltipraz	 is	 another	 dithiole-3-thiolone	 that	 has	 an	 interesting	 biological	 profile.	
Originally	identified	and	developed	as	a	drug	to	treat	schistosomiasis	(snail	fever),	a	
disease	caused	by	a	parasitic	 tapeworm	endemic	 to	 tropical	developing	countries,	
Oltipraz	has	since	been	shown	to	protect	against	carcinogenesis	 in	several	organs,	
including	breast,	colon,	pancreas,	lung,	stomach,	skin,	and	the	bladder117,118.	Oltipraz	





























of	 ecFabH,	 and	 the	 alkene	 functionality	 at	 the	 distal	 end	 of	 the	 isoprenoid	 tail	







































(C4),	 with	 reported	 IC50	 values	 of	 980	 nM	 and	 5.7	 μM	 for	 saFabH	 and	 ecFabH	
respectively121,123.	 Interestingly,	 in	 a	 separate	 study	 HR12	 was	 identified	 as	 a	 hit	
against	 E.	 coli	 uridine	 diphosphate-N-acetyl	 glucosamine	 enolpyruvyl	 transferase	








end	 of	 an	 a,b-unsaturated	 ketone	 functionality	 could	 point	 towards	 a	 covalent	
modification	model	via	a	Michael-type	mechanism123,124.	The	authors	of	the	ecMurA	
















R1 = Ph, Cl





















the	 antibacterial	 activity	 derived	 from	 these	 compounds	 is	 specific	 against	 either	
MurA	or	FabH.	However,	the	cell-based	assays	show	that	the	compounds	are	able	to	










































































Upon	 initial	 examination,	 the	 Michael-type	 acceptor	 nature	 of	 the	 cyclic	 a,b-
unsaturated	 ketone	 of	 HR45	 suggested	 to	 us	 that	 it	 may	 act	 as	 a	 pan	 assay	










to	 elucidate	 the	 mode	 of	 action	 of	 the	 compound	 on	 FabH.	 The	 aim	 of	 the	






















































































































is	 further	 delocalised	 over	 C4	 and	 C3	 (with	 double-bond	 character)	 and	 onto	 the	
carbonyl	 oxygen,	 consistent	 with	 the	 enolate	 intermediate	 formed	 during	 the	
proposed	addition	reaction’	(see	fig.	3.10).		
	
















purchased	as	a	 codon-optimised	gene	 from	Genscript	with	 the	 introduction	of	5’-
Nco1	and	3’-BamH1	restriction	sites.	The	synthetic	gene	was	excised	from	the	pUC-















Figure	 3.11	 -	 SDS-PAGE	 of	 fractions	 containing	 saFabH	 from	 nickel	 affinity	
chromatography	 (lanes	 1-5)	 and	 SEC	 (lanes	 6-10),	 and	 the	 SEC	 chromatogram	







of	 the	 N-terminal	 histidine	 tag,	 a	 common	 post-translational	 modification	 of	
recombinant	proteins	expressed	 in	E.	coli131.	There	were	also	 further	peaks	 in	 the	















this	 the	 FabH	 gene	was	 amplified	 from	 the	 pET-28a	 vector	 by	 PCR	 using	 primers	





the	 protein	 to	 be	 expressed	 and	 purified	 as	 previously,	 however	 after	 the	 nickel	





















the	 existence	 of	 a	 covalent	 reaction	 between	 saFabH	 and	 HR45.	 We	 began	 by	
incubating	a	12	µM	sample	of	 saFabH	 that	had	been	exchanged	 into	 fresh	buffer	
containing	 no	 reducing	 agent	 with	 HR45	 in	 approximately	 20-fold	 excess	 for	 30	
minutes	 at	 room	 temperature.	 This	 resulted	 in	 a	 quantitative	 shift	 of	 the	
deconvoluted	mass	of	+150	Da,	a	mass	shift	corresponding	to	the	addition	of	HR45	
with	the	loss	of	a	HCl.	This	data	gratifyingly	supported	our	working	hypothesis	of	a	












(NEM).	 NEM	 is	 a	 reagent	 commonly	 used	 in	 MS	 to	 selectively	 alkylate	 cysteine	
residues.	On	incubation	of	saFabH	with	10	mM	NEM	for	30	minutes	a	mass	shift	of	
+125	Da	was	observed,	corresponding	to	the	alkylation	of	a	single	cysteine	residue.	






















modified	 and	 native	 saFabH	 was	 carried	 out	 overnight	 under	 optimal	 conditions	
(ammonium	bicarbonate,	pH	8.0,	37	 °C).	 The	mixture	was	 cleaned	up	using	a	 c18	
ZipTip	cartridge	and	infused	into	a	12T	SolariX	FT-ICR	spectrometer.	As	well	as	the	
absence	 of	 the	 ion	 corresponding	 to	 the	 C112-containing	 tryptic	 peptide	 (103-








digest.	 We	 solved	 this	 problem	 by	 conducting	 a	 large-scale	 trypsin	 digest	 of	
unmodified-saFabH,	followed	by	incubation	with	activated	thiol	sepharose.	This	was	
to	 allow	 us	 to	 capture	 the	 cysteine-containing	 peptide	 (103-
VASMDQLAACSGFMYSMITAK-123)	on	the	activated	thiol	sepharose	solid	phase	and	
wash	 away	 all	 other	 non-cysteine	 containing	 peptides,	 before	 eluting	 the	 desired	
peptide	by	adding	the	reducing	agent	DTT.	The	peptide	was	desalted,	lyophilised	and	
resuspended	in	either	ammonium	bicarbonate	(pH	8.0)	or	ammonium	acetate	(pH	














latter	 corresponds	 to	 the	addition	of	150	Da,	 consistent	with	observations	on	 the	
intact	protein	(fig.	3.16).	In	ammonium	bicarbonate	(pH	8.0)	the	unmodified	peptide	
was	 found	 to	 exist	 predominantly	 as	 a	 [M+4H]4+	 disulfide	 dimer,	 as	 disulfide	
formation	 is	 favoured	 at	 alkaline	 pH	 approaching	 the	 pKa	 of	 cysteine	 (8.3).	
Perplexingly,	 incubation	 of	 the	HR45-modified	 peptide	 in	 ammonium	bicarbonate	
resulted	in	a	mass	shift	of	-184	Da	from	the	expected	HR45	modified	peptide	mass,	

















Figure	 3.16	 -	 Purified	 tryptic	 peptide	 (103-VASMDQLAACSGFMYSMITAK-123)	 in	 a)	
ammonium	acetate	(100	mM,	pH	7.0)	for	16	h	at	37	°C	and	b)	ammonium	bicarbonate	
(100	mM,	pH	8.0)	for	16	h	at	37	°C.	The	purified	peptide	modified	with	HR45	in	c)	









that	 one	 of	 the	 hydrolysis	 products	 facilitates	 the	 transformation,	 possibly	 by	 a	














is	essential	 for	sufficiently	 increasing	 the	nucleophilicity	of	 the	active	site	cysteine	
residue.	Whether	the	increase	in	pKa	of	C112	due	to	the	absence	of	this	effect	in	the	



































desalting	 and	 infusion	 into	 a	 12T	 SolariX	 FT-ICR	 mass	 spectrometer,	 the	 crucial	
cysteine	containing	tryptic	peptides	AACSGF	and	AACSGFMOx	(MOX	denotes	oxidation	




and	 AAC*SGFMOx,	 where	 C*	 denotes	 a	 cysteine	 modification	 of	 +150	 Da,	
corresponding	 to	 addition	 of	 HR45	with	 the	 loss	 of	 HCl.	 The	 two	most	 abundant	
isotopes	of	chlorine	are	35Cl	and	37Cl,	 in	an	approximate	ratio	of	3:1.	This	gives	the	
presence	of	chlorine	a	very	distinctive	appearance	in	a	mass	spectrum,	with	an	M+2	
peak	 of	 a	 third	 of	 the	 intensity.	 Gratifyingly,	 the	 HR45-modified	 peptide	 signals	
displayed	a	diagnostic	isotope	pattern	consistent	with	the	35Cl	and	37Cl	isotopes	in	a	
3:1	 ratio,	 a	 characteristic	 not	present	 in	 the	unmodified	peptides.	 To	 confirm	 the	
cysteine	residue	as	the	site	of	modification,	CID	tandem	MS	was	used	to	fragment	






































‘The	 X-ray	 structure	 of	 HR45	 was	 obtained	 from	 the	 CCDC	 (CCDC	 Number:	
1517056)134.	The	coordinates	for	a	Cysteine-HR45	C5-SG	adduct	were	produced	using	
JLigand135;	and	 the	adduct	was	 then	manually	docked	 into	 the	crystal	 structure	of	
saFabH	to	replace	Cys112	(PDBID:	3IL7)105	and	adjusted	to	minimise	steric	clashes	and	
to	maximize	hydrogen	bonding	potential	using	coot136.	The	resulting	model	was	then	









Although	 there	 is	 ample	 space	 for	 HR45	 in	 the	 active	 site,	 catalytically	 essential	
cysteine-112	residue	has	little	freedom	of	movement,	limiting	the	likely	positions	of	
the	ligand.	Interestingly,	our	model	suggested	there	was	hydrogen	bonding	between	
the	 C3	 carbonyl	 of	HR45	 and	 the	 side	 chain	 of	 catalytically	 essential	N26867.	 This	










































some	 degree	 of	 non-specific	 adduct	 formation.	 Despite	 this,	 we	 suggest	 that	 the	






We	 have	 also	 shown	 that	 the	 likely	 reason	 that	 this	 covalent	 modification	 has	




























or	 at	 30k	 resolution	 followed	 by	 4	 7500	 resolution	 Orbitrap	 MSMS	 spectra.	 In	
additional	analyses,	candidate	modified	peptides	were	fragmented	in	the	Orbitrap,	
as	above,	but	using	a	data	independent	inclusion	list.	MSMS	spectra	were	converted	




2	µL	 of	 each	 protein	 sample	 (10	µM)	was	 injected	 onto	 a	 1	 x	 250	mM	analytical	
















































































































































pH	 7.6,	 300	mM	NaCl,	 10%	 glycerol)	was	 added	HCl	 (100	µL,	 final	 conc.	 0.04	N).		























T: FTMS + p NSI w Full ms2 706.13@cid35.00 [180.00-870.00]

















































































shocked	at	42	 °C	 for	30	seconds	and	set	back	on	 ice	 for	a	 further	2	minutes.	SOC	
media	 (100	μL)	was	added	and	 the	mixture	was	agitated	at	37	 °C	 for	1	hour.	The	
mixture	was	spread	on	LB	agar	(100	μg/mL	ampicillin)	and	incubated	overnight	at	37	
AAC(DDCP)SGFMox
T: FTMS + p NSI w Full ms2 853.16@cid35.00 [220.00-870.00]







































































The	 reactions	were	 incubated	at	37	 °C	 for	2	hours	and	 loaded	directly	onto	a	1%	
agarose	gel	(TAE	buffer,	0.01%	gel	red).	A	band	from	each	experiment	corresponding	
to	the	saFabH	gene	and	the	empty	pET-28a	vector	(at	approx.	1000	bp	and	approx.	




















media	 (100	μL)	was	added	and	 the	mixture	was	agitated	at	37	 °C	 for	1	hour.	The	
mixture	was	spread	on	LB	agar	(30	μg/mL	kanamycin)	and	incubated	overnight	at	37	































and	 Xho1	 restriction	 enzymes.	 The	 product	 from	 the	 ligation	 reaction	 was	















(2	 x	 250	mL,	 30	 μg/mL	 kanamycin)	 and	 agitated	 overnight	 at	 37	 °C.	 	 One	 of	 the	









N-Terminal	 histidine-tagged	 saFabH	 was	 purified	 at	 4	 °C	 by	 Ni-affinity	
chromatography	 followed	by	 size	 exclusion	 chromatography.	 	 The	BL21	 (DE3)	 cell	
pellet	expressing	FabH	was	resuspended	in	lysis	buffer	(30	mL,	20	mM	Tris-HCl	pH	













Tris-HCl	pH	7.6,	300	mM	NaCl,	 10%	glycerol)	 at	4	 °C	 for	16	h	using	8	 kDa	MWCO	
dialysis	tubing.		The	reaction	mixture	was	then	injected	onto	a	HisTrap	5	mL	(GE)	Ni2+-
affinity	chromatography	column	pre-equilibrated	in	lysis	buffer	(30	mL,	20	mM	Tris-




exclusion	 chromatography	 (HiLoad	 Superdex	 200	 16/60,	 GE	 Healthcare)	 with	 an	
isocratic	elution	of	mobile	phase	buffer	 (500	mL,	20	mM	Tris-HCl	pH	7.6,	100	mM	
NaCl,	 10%	glycerol)	 at	 1	mL/min	over	 120	minutes.	 The	 saFabH	protein	 eluted	 at	

















OD600	 reached	 0.6,	 at	 which	 point	 the	 temperature	 was	 reduced	 to	 20°C	 and	
expression	 was	 induced	 by	 addition	 of	 IPTG	 (final	 conc.	 0.4	 mM).	 	 Cells	 were	
harvested	after	a	further	16	h	at	20	°C	and	subsequently	stored	at	-20	°C.	
	






injected	 onto	 a	 HisTrap	 5	 mL	 (GE)	 Ni2+-affinity	 chromatography	 column	 pre-
equilibrated	in	lysis	buffer.		The	column	was	washed	with	lysis	buffer	(5	CV)	before	
the	histidine-tagged	protein	was	eluted	using	a	gradient	(0-100%)	of	lysis	buffer	to	












10%	glycerol)	 at	 1	mL.min-1	 over	 120	minutes.	 TEV	protease	eluted	at	 approx.	 80	





























Dynamic	 combinatorial	 chemistry	 is	 a	 powerful	 tool	 to	 identify	 new	 ligands	 for	
biological	targets,	however	the	technique	has	failed	to	gain	traction	in	industrial	drug	
discovery	due	to	difficulties	in	deconvoluting	large	DCLs.	In	this	chapter,	we	seek	to	







forms	 of	Mtb.	 The	 DCL	 was	 developed	 around	 the	 well-studied	N-acylhydrazone	
(NAH)	exchange	reaction	to	explore	the	interaction	of	hydrazide	inhibitors	with	the	
aldehyde	moiety	of	the	PLP	cofactor.	From	the	28-membered	DCL,	4	privileged	PLP-








(WHO)	 estimates	 that	 1	 in	 3	 people	 is	 infected	 with	 TB,	 although	 90%	 of	 these	
infections	are	latent	and	not	immediately	contagious.	In	2015,	there	were	8	million	
newly	 infected	 patients	 and	 almost	 2	 million	 deaths,	 with	 95%	 of	 these	 cases	
occurring	 in	 developing	 countries138.	 TB	 has	 a	 particularly	 high	 mortality	 rate	 in	





treatment	 for	 TB	 is	 a	 6-month	 combination	 therapy	 of	 isoniazid,	 rifampicin,	
pyrazinamide	and	ethambutol	(HRZE)141.	A	combination	of	the	protracted	nature	of	
this	therapy	with	unpleasant	side	effects	and	inadequate	public	health	information	
often	 results	 in	 low	patient	 compliance.	 This,	 combined	with	 a	 limited	 and	dated	
arsenal	of	anti-TB	drugs	has	led	to	rapid	emergence	of	both	multidrug	resistant	TB	















with	a	valeric	acid	 tail	attached	to	 the	 latter	 (see	 fig.	4.1).	Many	plants,	 fungi	and	
micro-organisms	 are	 biotin	 autotrophs,	 synthesising	 the	 cofactor	 de	 novo.	 In	
contrast,	 mammals	 are	 unable	 to	 synthesise	 biotin	 and	 must	 obtain	 it	 from	
exogenous	 sources,	 such	 as	 from	 their	 gut	 microbiota	 or	 dietary	 intake144.	 The	












well	 documented	 of	 which	 is	 the	 biotin	 transporter	 protein	 (BioY),	 however	
homologues	in	the	Mtb	genome	remain	elusive143,145.	In	Mtb,	biotin	is	essential	for	
the	enzymes	pyruvate	carboxylase	and	acyl-CoA	carboxylase,	fundamental	proteins	
involved	 in	 the	 Krebs	 cycle	 and	 fatty	 acid	 biosynthesis,	 respectively143.	 Knockout	
studies	 of	 the	 biotin	 biosynthesis	 enzymes	 of	Mtb	 have	 shown	 the	 pathway	 is	
essential	 for	 survival	 both	 in	 vitro	 and	 in	 vivo146,147.	 The	 final	 four	 steps	 in	 biotin	
biosynthesis	are	conserved	across	all	biotin	autotrophs,	which	are	catalysed	by	8-








































































reaction.	Mouse	models	 using	 tetracycline-regulated	BioA	expression	have	 shown	
that	 the	 enzyme	 is	 essential	 not	 only	 for	 establishing	 an	 infection,	 but	 also	
maintaining	 bacterial	 persistence147.	 Park	et	 al.	also	 generated	 a	 deletion	mutant	
DbioA,	showing	it	was	not	viable	in	biotin-free	media,	even	when	supplemented	with	
AON.	 Perplexingly,	 they	 showed	 that	 growth	 could	 be	 rescued	 on	 addition	 of	
dethiobiotin	 (DTB)	 or	 biotin,	 suggesting	 that	 Mtb	 was	 indeed	 able	 to	 recruit	





















the	 cofactor	 forming	pyridoxamine	phosphate	 (PMP),	which	 is	 sequestered	 in	 the	
active	site.	PMP	then	forms	an	imine	with	the	second	substrate,	AON,	which	retains	
the	amino	group	when	it	is	displaced	by	Lys283,	forming	DAN	and	returning	BioA	to	
its	 original	 PLP-bound	holo	 form	 (see	 fig.	 4.5)149,150.	 It	 is	 interesting	 that	BioA	has	
















































with	 PLP,	 driven	 by	 aromatisation	 of	 the	 cyclohexadiene	 ring154.	 The	 compound	
showed	 specific	 activity	 against	 Mtb	 among	 a	 selection	 of	 40	 bacterial	 strains	
analysed155.	Shi	et	al.	characterised	a	reduced	version	of	ACM	lacking	the	primary	
amine	 with	 better	 whole-cell	 potency,	 and	 developed	 a	 mechanism-based	 BioA	










































any	 inhibitory	activity.	They	hypothesised	 that	 the	hydrazones	 formed	had	similar	
stability	to	the	Schiff	base	formed	between	the	cofactor	and	Lys283,	so	they	were	
readily	 reversible	 in	 the	 presence	 of	 substrates.	 Despite	 this,	 they	 were	 able	 to	
structurally	 characterise	 the	 covalent	 PLP-adducts	 formed	 by	 4	 library	 members	
(amine	 C1,	 PDB:	 4MQ0;	 hydrazine	 C2,	 PDB:	 4MQP;	 hydrazide	 C3,	 PDB:	 4MQQ;	
hydrazide	C4,	PDB:	4MQR).	The	binding	mode	of	the	PLP	motif	remains	unchanged	in	
all	 of	 the	 structures,	 and	 the	 hydrazine	 and	 hydrazide	motifs	 all	 retain	 the	 same	
binding	 conformation	 through	 the	 nitrogen-nitrogen	 double	 bond	 and	 carbonyl	
functionality	(in	the	case	of	4MQQ	and	4MQR),	however	the	distal	rings	of	each	hit	
all	 explore	 different	 space	 within	 the	 same	 binding	 pocket.	 Although	 no	 potent	

















was	 identified	as	an	 inhibitor	of	analogous	E.	 coli	BioA	 (ecBioA)158.	A	 library	of	24	






















There	 is	 therefore	 a	 strong	 precedent	 in	 the	 literature	 that	 aryl	 hydrazides	 could	
provide	a	basis	for	the	development	of	BioA	inhibitors.	By	using	diverse	hydrazides,	
it	may	be	possible	to	further	map	favourable	interactions	that	lead	to	strong	binding	







Electrospray	 ionisation	mass	spectrometry	(ESI-MS)	 is	a	relatively	gentle	 ionisation	
process	that	is	used	to	visualise	intact	proteins.	It	is	favourable	over	other	ionisation	
techniques	 that	 are	 prone	 to	 causing	 the	 protein	 to	 fragment.	 In	 ESI-MS,	 a	 high	
voltage	 is	applied	 to	 the	protein	solution,	 forming	highly	charged	droplets.	As	 the	





























with	 0.1%	 formic	 or	 acetic	 acid.	 This	 acidification	 disrupts	 the	 hydrogen	 bonding	
maintaining	 the	 tertiary	 structure	 of	 the	 macromolecule,	 causing	 the	 protein	 to	
unfold	and	expose	many	basic	groups	 that	can	be	protonated,	 resulting	 in	a	wide	
charge	state	distribution	(see	fig.	4.10).	
	
It	 is	 also	 possible	 to	 visualise	 a	 protein	 in	 its	 folded	 state	 under	 non-denaturing	
conditions.	By	incubating	the	target	with	a	compound,	or	library	of	compounds,	and	




than	1	mM160.	 Because	 the	protein	 remains	 folded,	 only	 a	 few	groups	 capable	of	
carrying	a	charge	are	exposed,	resulting	in	a	much	narrower	charge	state	distribution	
than	 under	 denaturing	 conditions.	 Naturally,	 this	 makes	 the	 ionisation	 and	














complex	with	 substrates,	 natural	 products	 and	 small	molecules54,160–162.	 The	 huge	
benefit	 in	 using	 non-denaturing	 ESI-MS	 in	 a	 screening	 campaign,	 is	 that	 binding	
ligands	can	be	immediately	 identified	by	the	m/z	 increase	that	they	impart	on	the	
protein	mass.	In	the	case	of	isobaric	ligands,	tandem	MS	experiments	can	be	used	to	















a	 known	 recognition	 element	 for	 CA	 inhibition.	 The	 library	 was	 composed	 of	 2	
aldehydes,	 one	 with	 the	 sulfonamide	 and	 one	 without,	 and	 5	 hydrazides.	 After	
allowing	the	DCL	to	equilibrate	for	40	h	in	the	absence	of	any	nucleophilic	catalyst,	
the	 library	 was	 infused	 under	 non-denaturing	 conditions	 and	 analysed	 using	 ESI	
Fourier-transform	mass	 spectrometry	 (ESI-FTMS)	 in	 negative	 ion	mode.	 The	 non-
denatured	control	mass	spectrum	of	CA	showed	a	tight	charge	state	envelope	of	9-,	
10-	 and	 11-	 charge	 states.	 The	 CA-templated	DCL	 non-denaturing	mass	 spectrum	
showed	 the	 same	 charge	 states,	 each	 being	 composed	 of	 a	 group	 of	 signals	
corresponding	to	bound	N-acylhydrazones.	
	
Poulsen	 assigned	 the	 CA-bound	N-acylhydrazones	 by	 tandem	mass	 spectrometry,	
tuning	 the	 collision	 energy	 to	 cause	 the	 protein-ligand	 complexes	 to	 dissociate,	
resulting	in	a	spectrum	with	both	signals	corresponding	to	apo-CA,	and	to	the	NAHs	
that	had	been	ejected.	Of	the	10	possible	N-acylhydrazones,	only	the	5	containing	
the	 sulfonamide	 recognition	 element	 were	 detected,	 and	 a	 CA	 binding	 assay	















to	 the	 metal39.	 They	 then	 characterised	 boronate	 ester	 exchange	 as	 a	 reaction	
suitable	for	protein-templated	DCC	by	NMR,	and	developed	this	chemistry	into	a	DCL	
targeting	 prolyl	 hydroxylase	 domain	 isoform	 2	 (PHD2),	 a	 2-oxoglutarate	 (2OG)	
oxygenase	 of	 therapeutic	 interest	 because	 it	 regulates	 the	 human	 hypoxic	
response40,163.	They	successfully	used	non-denaturing	MS,	which	was	coined	dynamic	











Schofield	 et	 al.	 used	 DCMS	 to	 deconvolute	 an	 impressive	 38-membered	 thiol-
disulfide	 DCL	 targeting	 another	 2OG	 oxygenase	 from	 E.	 coli,	 AlkB38.	 Their	 DCMS	










eluent	 protein	 was	 denatured	 with	 acetonitrile	 to	 release	 any	 bound	 molecules,	
followed	by	MS	analysis.	The	presence	of	NAG	was	confirmed	in	the	analysis,	so	they	
developed	an	imine	DCL	of	4	amines	including	glucosamine,	and	10	aldehydes.	They	

















obtained	 by	 MS	 analyses	 circumvent	 the	 limitations	 on	 library	 size	 and	 the	
requirement	to	 individually	synthesise	 library	members	that	are	often	 imposed	by	
spectral	 and	 chromatographic	 analysis	 techniques.	 Further	 validation	 of	 DCL	 MS	

















The	 BioA	 gene	 from	Mtb	 was	 gifted	 to	 us	 by	 the	 Aldrich	 group	 (University	 of	
Minnesota)	in	a	pUC-19	vector	with	an	N-terminal	hexahistidine	tag.	The	protein	was	
expressed	 in	 BL21(DE3)	 Rosetta	 2	 E.	 coli	 cells	 using	 literature	 conditions	 with	
expression	under	the	control	of	the	lac	promoter51.	After	the	cells	were	harvested,	a	
two-stage	purification	was	conducted	using	nickel	affinity	chromatography	followed	































K283A	 mtBioA	 was	 expressed	 in	 BL21(DE3)	 Gold	 E.	 coli	 cells	 following	 a	 poor	
expression	test	in	the	BL21(DE3)	Rosetta	strain.	Aside	from	the	expression	strain,	the	
mutant	protein	was	expressed	and	purified	by	the	same	method	as	the	WT	enzyme.	





















The	BioA	gene	 from	E.	 coli	was	provided	by	Annabel	 Serpico	 (Campopiano	group,	
Edinburgh)	in	a	pET-28a	vector	with	an	N-terminal	hexahistidine	tag.	The	protein	was	
expressed	 in	 BL21(DE3)	E.	 coli	 cells	 using	 conditions	 that	 had	 been	 optimised	 for	
ecBioA	expression.	Protein	overexpression	was	induced	through	the	T7	promoter	by	
the	addition	of	0.5	mM	IPTG	followed	by	agitation	at	30	°C	for	5	h.	After	the	cells	were	
harvested,	 a	 two-stage	 purification	 was	 conducted	 using	 nickel	 affinity	


























As	 such,	 a	 library	 of	 hydrazides	 was	 assembled	 from	 a	 mix	 of	 synthetic	 and	
commercially	available	compounds,	along	with	compounds	obtained	 from	the	NCI	
Developmental	 Therapeutic	 Program’s	 open	 compound	 library	




The	5	 amino	acid-derived	hydrazides	were	 synthesised	during	 a	Masters	 research	
project	 by	 Jue	 Theresa	 Wang,	 aiming	 at	 increasing	 the	 aqueous	 solubility	 of	
subsequent	 N-acylhydrazones.	 These	 compounds	 were	 included	 in	 the	 library	
targeting	BioA,	as	the	aminotransferase	class	of	enzymes	often	utilise	amino	acids	as	
















































































































































































Prior	 to	 the	 DCC	 experiment,	 differential	 scanning	 fluorimetry	 (DSF)	 was	 used	 to	








PLP	 from	 the	 catalytic	 lysine	 results	 in	 a	 destabilising	 thermal	 shift51,152,168.	 They	
report	a	melting	temperature	of	86	°C	for	mtBioA,	agreeing	with	our	experimental	
value	 of	 87	 °C	 (see	 fig.	 4.21).	 Through	 altered	 purification	 procedures,	 they	 also	
attributed	a	melting	temperature	of	68	°C	to	the	apo	form	of	the	protein,	confirming	




















external	 aldimine	 stage	 of	 the	 BioA	 catalytic	 cycle51.	 The	 polarity	 of	 the	 binding	
pocket	differs	between	ecBioA	and	mtBioA,	hence	a	given	PLP-NAH	may	be	more	


























Upon	attempting	 this	 approach	with	both	mtBioA	and	ecBioA	we	were	unable	 to	




















in	 its	holo-form.	 A	 buffer	 exchange	 step	 to	 remove	 the	 excess	 unbound	 PLP	was	
carried	out	using	a	Bio-Spin	P-6	(Bio-Rad)	column,	which	facilitates	a	buffer	exchange	
of	over	99.9%.	The	BioA-templated	28-member	DCL	was	then	assembled	with	the	







with	 gentle	 shaking,	 followed	 by	 a	 P-6	 buffer	 exchange	 into	 50	 mM	 ammonium	
bicarbonate.	 This	 served	 to	 both	 remove	 any	 of	 the	 hydrazide	 members	 that	
remained	unbound,	and	exchange	the	protein	ligand	complex	into	a	volatile	buffer	
system	suitable	 for	ESI-MS	 infusion.	Prior	 to	 infusion,	 the	sample	was	diluted	to	a	
final	 protein	 concentration	 of	 10	 µM	 using	 a	 60%	methanol	 in	 0.1%	 formic	 acid	






















that	 the	 reduction	had	 taken	place.	This	was	confirmed	by	LCMS,	showing	a	clear	


























A	 second	 essential	 control	was	 to	 ensure	 that	 all	 of	 the	NAH	DCL	 products	were	
forming	 under	 the	 conditions	 used	 for	 the	 DCL	 experiment	 (see	 fig.	 4.28).	 To	






approach	 was	 required.	 The	 reaction	 was	 successfully	 exchanged	 into	 a	 volatile	
buffer	system	using	a	C18	zip-tip	(Millipore).	This	bound	the	NAH	DCL	products	but	
not	the	unbound	hydrazides,	which	were	eluted.	The	NAH	DCL	products	were	then	





























































































































Relative	 signal	 intensities	 of	 DCL	 products	 from	 the	 protein-templated	 DCC	
experiments	were	converted	to	%	total	product	population,	correcting	for	ionisation	
efficiency	based	on	the	relative	intensities	in	the	excess	PLP	blank	DCL	control.	This	
















































favourable	 binding	 interactions	 with	 the	 amino	 acid	 derived	 primary	 amine	
functionality,	 the	 compounds	 were	 crystallised	 with	 mtBioA	 following	 literature	


































the	 primary	 amine	 group.	 The	 indole	 ring	 appeared	 to	 stack	 between	 residues	




















of	 the	 dynamic	 equilibrium	 rather	 than	 a	 kinetic	 result	 of	 enzymatic	 activity,	 we	
templated	the	same	DCL	with	catalytically	inactive	mutant	K283A.	The	K283A	mtBioA	
templated	 DCL	 appears	 to	 broadly	 amplify	 the	 same	 compounds	 as	 the	 WT-







































































There	 is	 a	 striking	 difference	 between	 the	 DCC	 results	 templated	 by	mtBioA	 and	






































previous	 experiments.	 Only	 the	 single	 hydrazide	 NAH1	 was	 observed	 in	 the	 1-










































































systems.	 If	 the	 compounds	 succeed	 in	 entering	 the	 cell,	 their	 amino	 acid	 derived	
structure	may	allow	them	to	be	removed	by	a	number	of	amino	acid	transporters.	
The	 fact	 that	 isoniazid	 and	 MAC13772	 both	 show	 excellent	 activity	 against	Mtb	





























An	MIC	 of	 125	µg/mL	 can	 be	 ascribed	 to	H14	 against	 E.	 coli.	 Although	 no	 other	

















transport	 protein	 BioY,	 and	were	 therefore	 thought	 to	 be	 dependent	 on	de	 novo	
biotin	biosynthesis143,145,171.	Recently	another	biotin	transporter	protein,	YigM,	was	





























































on	 the	protein	melting	 temperature.	While	 destabilising	 thermal	 shifts	 are	 still	 of	
interest	in	drug	discovery,	their	correlation	to	binding	strength	is	not	as	clear	cut	as	
the	more	traditional	approach	of	identifying	fragments	that	exert	stabilising	thermal	




We	 showed	 that	 every	 PLP-NAH	 product	 was	 detectable	 under	 DCC	 reaction	
conditions.	 On	 the	 assumption	 that	 the	 concentration	 of	 the	 PLP-NAHs	 was	
approximately	equal	at	equilibrium,	this	allowed	us	to	convert	an	intensity	value	in	
the	mass	 spectrum	to	a	 relative	 concentration	value,	making	 the	 results	easier	 to	
compare.	Interestingly	the	DCC	experiments	with	ecBioA	and	mtBioA	selected	6	and	









Compounds	 H11,	 H12,	 H13,	 H14,	 and	 H17	 were	 submitted	 for	 in	 vivo	
characterisation,	 and	 although	 there	 was	 no	 detectable	 activity	 against	 M.	










































N-Terminal	 histidine-tagged	 ecBioA	 was	 purified	 at	 4	 °C	 by	 Ni-affinity	






















An	 aliquot	 (50	 μL)	 of	 BL21	 Rosetta	 2	 (DE3)	 cells	 was	 transformed	 with	 the	
mtBioA/pUC-19	 plasmid	 and	 set	 on	 ice	 for	 25	minutes.	 The	 cells	 were	 then	 heat	
shocked	at	42	 °C	 for	40	seconds	and	set	back	on	 ice	 for	a	 further	2	minutes.	SOC	










resuspended	 in	 lysis	buffer	 (50	mM	HEPES	pH	7.5,	500	mM	NaCl,	 1	mM	MgCl2,	 1	
mg/mL	lysozyme,	0.1	mM	TCEP)	lysed	for	15	minutes	with	rounds	of	30	second	of	
sonication	 followed	 by	 30	 seconds	 of	 rest.	 Excess	 cell	 matter	 was	 removed	 by	
centrifugation	(18,000	g,	30	minutes,	4	°C)	and	the	supernatant	was	injected	onto	a	
HisTrap	 1	 mL	 (GE)	 Ni2+-affinity	 chromatography	 column	 pre-equilibrated	 in	 wash	






























in	 the	 linear	 range	of	 1.4	 –	 0.1	mg/mL	 (1.4,	 1.0,	 0.7,	 0.5,	 0.35,	 0.25	mg/mL).	 The	
protein	sample	concentration	was	estimated	using	the	Beer-Lambert	equation	with	
the	 calculated	 extinction	 coefficient	 of	 the	 protein	
(http://web.expasy.org/protparam)	and	 the	absorbance	of	 the	 sample	at	280	nm.	






























PLP	 internal	 aldimine,	 and	 desalted	 (25	 mM	 HEPES	 pH	 7.5,	 50	 mM	 NaCl).	 The	
concentration	of	each	protein	sample	was	determined	by	Bradford	assay,	and	diluted	
to	 120	 µM	 with	 desalting	 buffer.	 The	 samples	 were	 used	 to	 prepare	 protein-





room	 temperature	 with	 gentle	 shaking	 overnight	 and	 then	 desalted	 (50	 mM	















containing	1.5%	DMSO.	 The	DCL	was	 incubated	at	 room	 temperature	with	 gentle	
shaking	 overnight	 and	 then	 a	 50	 µL	 aliquot	 was	 removed	 and	 desalted	 (50	 mM	
NH4HCO3).	To	the	remaining	150	µL	sample	was	added	22.5	µM	each	of	hydrazide	
H2-28	 to	maintain	 an	 equal	 DCL	 concentration.	 This	 DCL	 was	 incubated	 at	 room	
temperature	with	gentle	shaking	overnight	and	then	a	50	µL	aliquot	was	removed	


































and	 ΔyigM	 (blue)	 strains	 of	 Escherichia	 coli	 (E.	 coli).	 ΔyigM	 E.	 coli	 is	 the	 biotin	
transporter	deletion	E.	coli	mutant,	making	 it	significantly	more	sensitive	to	biotin	















to	 flat-bottomed	 96	 well	 plates	 containing	 two-fold	 serial	 dilution	 of	 the	 tested	
compounds	(256	-	1μg/mL)	and	incubated	at	37	°C	for	40	hours.	Optical	density	at	























































































residue	 was	 resuspended	 in	 acetone	 (30	 ml)	 and	 stirred	 for	 15	 minutes.	 The	
precipitate	was	collected	by	vacuum	filtration	and	washed	with	acetone	(3	x	10	ml)	

















































































eq.,	 1.64	 g,	 7.5	 mmol)	 were	 added	 to	 a	 solution	 of	 methyl	 (2S)-2-amino-4-































































































































Hydrazine	 solution	 (24-26%	 in	water,	 5.0	 eq.,	 3.00	 g,	 15.0	mmol)	was	 added	 to	 a	



























































for	 another	 3	 hours.	 The	 solution	 was	 concentrated	 in	 vacuo	 to	 yield	 the	 target	





























Hydrazine	 solution	 (24-26%	 in	water,	 5.0	 eq.,	 3.58	 g,	 17.9	mmol)	was	 added	 to	 a	
solution	of	methyl	(2S)-2-{[(tert-butoxy)carbonyl]amino}-2-phenylacetate	AE04	(1.0	
eq.,	 1.00	 g,	 3.6	mmol)	 in	methanol	 (10	ml)	 and	 stirred	 at	 reflux	 for	 5	 hours.	 The	
solution	was	then	concentrated	in	vacuo	to	yield	the	target	compound	AE12	(0.78	g,	
2.8	mmol,	78%)	as	an	off-white	solid:	MP	132-133°C;	IR	(cm-1)	3325,	1690,	1659,	1647,	










Hydrazine	 solution	 (24-26%	 in	 water,	 5.0	 eq.,	 1.68	 g,	 8.4	mmol)	 was	 added	 to	 a	
solution	 of	 tert-butyl	 N-[(1S)-1-(hydrazinecarbonyl)-2-(4-
hydroxyphenyl)ethyl]carbamate	 (1.0	 eq.,	 0.50	 g,	 1.7	 mmol)	 in	 a	 1:1	 mixture	 of	
tetrahydrofuran	and	methanol	(10	ml)	and	stirred	at	room	temperature	overnight.	


















































































































t-Butyl	 N-[(1S)-1-(hydrazinecarbonyl)-2-phenylethyl]carbamate	 AE12	 (1.0	 eq.,	 100	
mg,	0.36	mmol)	was	stirred	in	1	M	HCl	(2	ml)	at	room	temperature	overnight.	The	






































t-Butyl	N-[(1S)-1-(hydrazinecarbonyl)-3-methylbutyl]carbamate	 AE09	 (1.0	 eq.,	 100	
mg,	0.41	mmol)	was	stirred	in	1	M	HCl	(2	ml)	at	room	temperature	overnight.	The	









Hydrazine	 solution	 (24-26%	 in	water,	 5.0	 eq.,	 2.40	 g,	 12.0	mmol)	was	 added	 to	 a	
solution	 of	 ethyl-2,3-dihydrobenzo-1,4-dioxine-5-carboxylate	 (1.0	 eq,	 0.50	 g,	 2.4	




































Dynamic	 combinatorial	 chemistry	 is	 a	 powerful	 tool	 to	 identify	 new	 ligands	 for	
biological	 targets.	 The	 scope	 of	 suitable	 reversible	 reactions	 that	 proceed	 under	
thermodynamic	control	in	physiological	conditions	has	been	gradually	expanded	over	
the	 last	decades,	however	DCC	has	 thus	 far	 failed	 to	gain	 traction	as	a	 technique	
appropriate	for	drug	discovery	in	the	pharmaceutical	industry.	The	constraints	placed	
on	library	size	by	validated	analytical	techniques,	and	the	effort-intensive	reality	of	
this	academically	elegant	 concept	have	not	allowed	DCC	 to	develop	 into	a	broad-










In	 the	 first	 chapter	 of	 this	 thesis,	 we	 demonstrated	 the	 power	 of	 19F	 NMR	 for	
screening	DCLs.	This	non-invasive	analysis	method	was	used	 in	a	proof-of-concept	
study	 to	 identify	 inhibitors	of	 the	antimicrobial	 target	FabH	 from	E.	coli.	 In	 recent	
years	 this	 analysis	method	has	been	 adopted	 and	developed	 for	 the	 screening	of	
fragment	 libraries	 by	 the	pharmaceutical	 industry.	While	DCL	 size	 and	 complexity	
remain	limited	by	spectral	overlap,	it	is	our	hope	that	the	application	of	19F	NMR	to	









residue	 (Cys112).	 We	 determined	 that	 the	 failure	 of	 previous	 investigations	 to	
capture	 this	 adduct	 was	 due	 to	 the	 HR45-induced	 degradation	 of	 Cys112	 to	





Using	 a	 28-member	 DCL	 we	 identified	 hits	 against	 the	 recently	 validated	







primal	 evolutionary	 concepts	 at	 the	 core	 of	 the	 technique	 provide	 intrigue	 for	
exploring	different	chemical	systems,	and	elegant	experiments	can	give	us	the	most	
basic	 insight	 into	 the	 mysteries	 of	 cellular	 processes.	 However,	 only	 when	
sophisticated	 screening	methods	 are	 developed	 in	 line	 with	 the	 requirements	 of	
pharmaceutical	 industry,	 will	 the	 latent	 power	 of	 DCC	 be	 harnessed	 for	 drug	
discovery.	
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6	 Appendix	1		 Protein	amino	acid	sequences	
ecFabH/pET-28a	
predicted	MW	(ExPASy):	35678.45	Da	
MGSSHHHHHHSSGLVPRGSHMYTKIIGTGSYLPEQVRTNADLEKMVDTSDEWIVTRTGIRER
HIAAPNETVSTMGFEAATRAIEMAGIEKDQIGLIVVATTSATHAFPSAACQIQSMLGIKGCPAF
DVAAACAGFTYALSVADQYVKSGAVKYALVVGSDVLARTCDPTDRGTIIIFGDGAGAAVLAASE
EPGIISTHLHADGSYGELLTLPNADRVNPENSIHLTMAGNEVFKVAVTELAHIVDETLAANNLD
RSQLDWLVPHQANLRIISATAKKLGMSMDNVVVTLDRHGNTSAASVPCALDEAVRDGRIKPG
QLVLLEAFGGGFTWGSALVRF	
	
saFabH/pET-28a	
predicted	MW	(ExPASy):	36042.77	Da	
MGSSHHHHHHSSGLVPRGSHMNVGIKGFGAYAPEKIIDNAYFEQFLDTSDEWISKMTGIKER
HWADDDQDTSDLAYEASVKAIADAGIQPEDIDMIIVATATGDMPFPTVANMLQERLGTGKV
ASMDQLAACSGFMYSMITAKQYVQSGDYHNILVVGADKLSKITDLTDRSTAVLFGDGAGAVII
GEVSEGRGIISYEMGSDGTGGKHLYLDKDTGKLKMNGREVFKFAVRIMGDASTRVVEKANLTS
DDIDLFIPHQANIRIMESARERLGISKDKMSVSVNKYGNTSAASIPLSIDQELKNGKLKDDDTIVL
VGFGGGLTWGAMTIKWGK	
	
saFabH/pET-HISTEV	(cleavable	tag	underlined)	
predicted	MW	(ExPASy):	38346.38	Da	(35378.21	Da	cleaved)	
MSYYHHHHHHDYDIPTTENLYFQGAMGNVGIKGFGAYAPEKIIDNAYFEQFLDTSDEWISKM
TGIKERHWADDDQDTSDLAYEASVKAIADAGIQPEDIDMIIVATATGDMPFPTVANMLQERL
GTGKVASMDQLAACSGFMYSMITAKQYVQSGDYHNILVVGADKLSKITDLTDRSTAVLFGDG
AGAVIIGEVSEGRGIISYEMGSDGTGGKHLYLDKDTGKLKMNGREVFKFAVRIMGDASTRVVE
KANLTSDDIDLFIPHQANIRIMESARERLGISKDKMSVSVNKYGNTSAASIPLSIDQELKNGKLKD
DDTIVLVGFGGGLTWGAMTIKLQITRAPPPPPLRSGC	
	
mtBioA/pUC-19	
predicted	MW	(ExPASy):	48482.68	Da	
MGSSHHHHHHSSGLVPRGSHMAAATGGLTPEQIIAVDGAHLWHPYSSIGREAVSPVVAVAA
HGAWLTLIRDGQPIEVLDAMSSWWTAIHGHGHPALDQALTTQLRVMNHVMFGGLTHEPAA
RLAKLLVDITPAGLDTVFFSDSGSVSVEVAAKMALQYWRGRGLPGKRRLMTWRGGYHGDTFL
AMSICDPHGGMHSLWTDVLAAQVFAPQVPRDYDPAYSAAFEAQLAQHAGELAAVVVEPVV
QGAGGMRFHDPRYLHDLRDICRRYEVLLIFDEIATGFGRTGALFAADHAGVSPDIMCVGKALT
GGYLSLAATLCTADVAHTISAGAAGALMHGPTFMANPLACAVSVASVELLLGQDWRTRITELA
AGLTAGLDTARALPAVTDVRVCGAIGVIECDRPVDLAVATPAALDRGVWLRPFRNLVYAMPP
YICTPAEITQITSAMVEVARLVGSLP	
	
mtBioA/pUC-19	K283A	mutant	
predicted	MW	(ExPASy):	48425.58	Da	(purchased	fragment	underlined)	
MGSSHHHHHHSSGLVPRGSHMAAATGGLTPEQIIAVDGAHLWHPYSSIGREAVSPVVAVAA
HGAWLTLIRDGQPIEVLDAMSSWWTAIHGHGHPALDQALTTQLRVMNHVMFGGLTHEPAA
RLAKLLVDITPAGLDTVFFSDSGSVSVEVAAKMALQYWRGRGLPGKRRLMTWRGGYHGDTFL
AMSICDPHGGMHSLWTDVLAAQVFAPQVPRDYDPAYSAAFEAQLAQHAGELAAVVVEPVV
	
187	
QGAGGMRFHDPRYLHDLRDICRRYEVLLIFDEIATGFGRTGALFAADHAGVSPDIMCVGAALT
GGYLSLAATLCTADVAHTISAGAAGALMHGPTFMANPLACAVSVASVELLLGQDWRTRITELA
AGLTAGLDTARALPAVTDVRVCGAIGVIECDRPVDLAVATPAALDRGVWLRPFRNLVYAMPP
YICTPAEITQITSAMVEVARLVGSLP	
	
ecBioA/pET-28a	
predicted	MW	(ExPASy):	49498.92	Da	
MGSSHHHHHHSSGLVPRGSHMTTDDLAFDQRHIWHPYTSMTSPLPVYPVVSAEGCELILSDG
RRLVDGMSSWWAAIHGYNHPQLNAAMKSQIDAMSHVMFGGITHAPAIELCRKLVAMTPQP
LECVFLADSGSVAVEVAMKMALQYWQAKGEARQRFLTFRNGYHGDTFGAMSVCDPDNSM
HSLWKGYLPENLFAPAPQSRMDGEWDERDMVGFARLMAAHRHEIAAVIIEPIVQGAGGMR
MYHPEWLKRIRKICDREGILLIADEIATGFGRTGKLFACEHAEIAPDILCLGKALTGGTMTLSATL
TTREVAETISNGEAGCFMHGPTFMGNPLACAAANASLAILESGDWQQQVADIEVQLREQLAP
ARDAEMVADVRVLGAIGVVETTHPVNMAALQKFFVEQGVWIRPFGKLIYLMPPYIILPQQLQR
LTAAVNRAVQDETFFCQ	
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